>
Palantir Manifesto Shows The Clear Convergence Of Technofascism With Technocracy
Washington's Democrat ex-governor says she's disgusted at millionaires' tax...
The Odyssey Backlash Goes NUCLEAR - WTF Nolan?
He Got Banned From Selling Skateboards | Joe Rogan
US To Develop Small Modular Nuclear Reactors For Commercial Shipping
New York Mandates Kill Switch and Surveillance Software in Your 3D Printer ...
Cameco Sees As Many As 20 AP1000 Nuclear Reactors On The Horizon
His grandparents had heart disease.
At 11, Laurent Simons decided he wanted to fight aging.
Mayo Clinic's AI Can Detect Pancreatic Cancer up to 3 Years Before Diagnosis–When Treatment...
A multi-terrain robot from China is going viral, not because of raw speed or power...
The World's Biggest Fusion Reactor Just Hit A Milestone
Wow. Researchers just built an AI that can control your body...
Google Chrome silently installs a 4 GB AI model on your device without consent
The $5 Battery That Never Dies - Edison Buried This 100 Years Ago

Like the horse of Troy, scientists at the Technion have developed a way to sneak synthetic cells right into tumor tissue, where they then begin producing cancer-fighting proteins from the inside. The technique was tested in both cell cultures and in mice, and found to be an effective treatment in both cases.
Cancer cells thrive thanks to some robust defense mechanisms, so finding ways to get past them is a key area of research. In the past, scientists have sent gold nanoparticles inside tumors by hitchhiking on white blood cells, before heating the gold with near-infrared light to kill the cancer from within. Others examined the possibility of administering a "prodrug" that remained inactive until it detected cancer markers, and then began producing drugs from inside the tumor.
The new work follows a similar function as the latter. The Technion scientists loaded molecular machines inside lipid-based particles that resemble biological cell membranes, creating what they call "nano-factories." Once they're activated by sensing the presence of abnormal cells, these particles kick into gear, producing specific therapeutic proteins and pulling the energy and building blocks they need from the tumor tissue around them.
"By coding the integrated DNA template, the particles we developed can produce a variety of protein medicines," says Avi Schroeder, one of the lead researchers on the study. "They are modular, meaning they allow for activation of protein production in accordance with the environmental conditions. Therefore, the artificial cells we've developed at the Technion may take an important part in the personalized medicine trend – adjustment of treatment to the genetic and medical profile of a specific patient."